WBC
ANIK icon

Westpac Banking Corp’s Anika Therapeutics ANIK Stock Holding History

Westpac Banking Corp’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-23,600
Closed -$565K – 916
2013
Q3 		$565K Sell
23,600
-22,600
-49% -$507K 0.01% 702
2013
Q2 		$671K Buy
+46,200
New +$666K 0.01% 645

Other funds holding ANIK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Westpac Banking Corp's ANIK Position: Q4 2013 in Review

Westpac Banking Corp sold out of Anika Therapeutics (ANIK) in Q4 2013, closing a stake of 23,600 shares — an estimated $565K sold.

Westpac Banking Corp first reported a position in ANIK in Q2 2013 and held it in 2 quarters. The position peaked at $671K in Q2 2013. 146 funds tracked by Wall St. Rank hold ANIK as of Q4 2013.

  • Westpac Banking Corp reported no remaining Anika Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Westpac Banking Corp sold 23,600 Anika Therapeutics shares in Q4 2013, an estimated $565K.
  • Westpac Banking Corp first reported a position in Anika Therapeutics in Q2 2013 and held it in 2 quarters.
  • Westpac Banking Corp's Anika Therapeutics position peaked at $671K in Q2 2013.
  • 146 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2013.

Based on Westpac Banking Corp's 13F filing for Q4 2013, filed 13 Feb 2014.